Hennion & Walsh Asset Management Inc. Has $2.12 Million Position in MorphoSys AG (NASDAQ:MOR)

Hennion & Walsh Asset Management Inc. increased its position in MorphoSys AG (NASDAQ:MOR) by 71.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 116,901 shares of the company’s stock after buying an additional 48,710 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.08% of MorphoSys worth $2,121,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in MOR. Quadrant Capital Group LLC boosted its position in shares of MorphoSys by 204.8% in the fourth quarter. Quadrant Capital Group LLC now owns 5,572 shares of the company’s stock valued at $55,000 after acquiring an additional 3,744 shares during the period. Exchange Traded Concepts LLC boosted its position in shares of MorphoSys by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 17,437 shares of the company’s stock valued at $173,000 after acquiring an additional 4,421 shares during the period. Virtu Financial LLC bought a new stake in shares of MorphoSys in the fourth quarter valued at approximately $244,000. Henry James International Management Inc. bought a new stake in shares of MorphoSys in the fourth quarter valued at approximately $426,000. Finally, TD Asset Management Inc boosted its position in shares of MorphoSys by 153.8% in the fourth quarter. TD Asset Management Inc now owns 361,138 shares of the company’s stock valued at $3,575,000 after acquiring an additional 218,870 shares during the period. Institutional investors and hedge funds own 18.38% of the company’s stock.

MorphoSys Stock Performance

Shares of NASDAQ MOR traded up $0.03 during midday trading on Friday, reaching $18.20. 24,526 shares of the company traded hands, compared to its average volume of 73,660. The stock’s 50-day simple moving average is $18.21 and its 200-day simple moving average is $15.77. MorphoSys AG has a 12 month low of $4.18 and a 12 month high of $19.50. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 4.98.

MorphoSys (NASDAQ:MOR) last issued its quarterly earnings data on Monday, April 29th. The company reported ($2.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($1.73). MorphoSys had a negative net margin of 226.79% and a negative return on equity of 694.31%. The company had revenue of $29.86 million for the quarter, compared to the consensus estimate of $48.99 million. As a group, analysts forecast that MorphoSys AG will post -2.43 EPS for the current year.

Analysts Set New Price Targets

Separately, Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $18.25 target price (up from $17.00) on shares of MorphoSys in a research report on Thursday, March 14th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $11.78.

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.